Scott M. Rocklage joined the 5 AM Ventures in the year 2003 as a Venture Partner, and he was promoted to be a Managing Partner in the year 2004. Dr. Scott Rocklage has more than three decades of experience in healthcare management with strategic leadership roles that has led FDA to approve the three United States New Drug Applications (Omniscan™, Teslascan®, and Cubicin®).

Scott has successfully entered several drug candidates into clinical trials. Dr. Rocklage initially served as Chairman and the Chief Executive Officer of Cubist Pharmaceuticals. He was also the President and Chief Executive Officer of Nycomed Salutar.Rocklage has held various R&D positions at Salutar and Catalytica.

Dr. Rocklage has served as a Board Chairman of Relypsa and-and Novira; Johnson & Johnson acquired that. Dr. Rocklage has a Bachelor of Science in Chemistry which he received from the University of California, Berkeley. He also has a Ph.D. in Chemistry which he received after graduating from the Massachusetts Institute of Technology (MIT). Learn more about Scott Rocklage: and

This was where he successfully researched in Richard R. Schrock’s laboratory Scott Rocklage is an inventor or co-inventor on more than thirty United States patents and also has over one hundred peer-reviewed publications.

Scott reveals that his business is a science-based venture capital firm called 5 AM Ventures the company’s formation business is considered at a very early stage thus the name 5 AM which represents early.

Dr. Rocklage believes by working with entrepreneurs to help them shape their ideas into a reality. He is impressed with the explosive growth that can target specific mutations or genotypes with the aim of treating cancer in several ways.

Scott urges individuals who want to be successful entrepreneurs to be well organized in regards to time management and set their priorities right. Entrepreneurs should not be afraid of taking risks. They should do their best when it comes to controlling their future.

Read more: Idea Mensch | Scott Rocklage